FDA needs 3 more months to review cancer drug vandetanib

01/9/2011 | Google

The FDA pushed back an approval decision on vandetanib, a drug for medullary thyroid cancer, after maker AstraZeneca submitted a plan for risk evaluation and mitigation. The agency is scheduled to complete its review by April 7.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide